BioCryst Pharmaceuticals, Inc. announced that its oral Factor D inhibitor, BCX9930, demonstrated >99% suppression of the alternative pathway (AP), and that >98% suppression was maintained for 24 hours post-dosing, in patients with C3 glomerulopathy (C3G), a rare renal disease that is characterized by dysregulation of the AP of the complement system. The data, which are the first data with BCX9930 in patients with C3G, are being presented in a poster session at the 18th European Meeting on Complement in Human Disease, which is being held in Bern, Switzerland, from August 26-29, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.375 USD | -0.79% | -5.10% | -26.96% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.96% | 909M | |
-0.49% | 103B | |
+3.31% | 96.73B | |
+1.66% | 21.31B | |
-16.16% | 21.21B | |
-6.82% | 18.79B | |
-41.41% | 16.37B | |
-22.87% | 13.68B | |
+6.32% | 13.44B | |
+21.46% | 10.98B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients